A
Andrea T. Hooper
Researcher at Regeneron
Publications - 27
Citations - 2303
Andrea T. Hooper is an academic researcher from Regeneron. The author has contributed to research in topics: Medicine & Placebo. The author has an hindex of 7, co-authored 16 publications receiving 938 citations. Previous affiliations of Andrea T. Hooper include New York University.
Papers
More filters
Journal ArticleDOI
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
David M. Weinreich,Sumathi Sivapalasingam,Thomas Norton,Shazia Ali,Haitao Gao,Rafia Bhore,Bret J Musser,Yuhwen Soo,Diana Rofail,Joseph Im,Christina Perry,Cynthia Pan,Romana Hosain,Adnan Mahmood,John D. Davis,Kenneth C. Turner,Andrea T. Hooper,Jennifer D. Hamilton,Alina Baum,Christos A. Kyratsous,Yunji Kim,Amanda Cook,Wendy Kampman,Anita Kohli,Yessica Sachdeva,Ximena Graber,Bari Kowal,Thomas DiCioccio,Neil Stahl,Leah Lipsich,Ned Braunstein,Gary Herman,George D. Yancopoulos +32 more
TL;DR: In this interim analysis, the REGN-COV2 antibody cocktail reduced viral load, with a greater effect in patients whose immune response had not yet been initiated or who had a high viral load at baseline.
Journal ArticleDOI
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
Meagan P. O'Brien,Eduardo Forleo-Neto,Bret J Musser,Flonza Isa,Kuo-Chen Chan,Neena Sarkar,Katharine J. Bar,Ruanne V. Barnabas,Dan H. Barouch,Myron S. Cohen,Christopher B. Hurt,Dale R. Burwen,Mary A. Marovich,Peijie Hou,Ingeborg Heirman,John D. Davis,Kenneth C. Turner,Divya Ramesh,Adnan Mahmood,Andrea T. Hooper,Jennifer D. Hamilton,Yunji Kim,Lisa A. Purcell,Alina Baum,Christos A. Kyratsous,James Krainson,Richard Perez-Perez,Rizwana Mohseni,Bari Kowal,A. Thomas DiCioccio,Neil Stahl,Leah Lipsich,Ned Braunstein,G. Herman,George D. Yancopoulos,David M. Weinreich +35 more
TL;DR: The combination of the monoclonal antibodies casirivimab and imdevimab has been shown to markedly reduce the risk of hospitalization or... as discussed by the authors, which is known as REGN-COV2.
Journal ArticleDOI
In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis
David Zagzag,Andrea T. Hooper,David R. Friedlander,Wai Chan,Jocelyn Holash,Stanley J. Wiegand,George D. Yancopoulos,Martin Grumet +7 more
TL;DR: The results suggest that angiopoietins are involved in the early stage of vascular activation and in advanced angiogenesis, and they identify Ang-2 as an early marker of glioma-induced neovascularization.
Journal ArticleDOI
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Richard Copin,Alina Baum,Elzbieta Wloga,Kristen E. Pascal,Stephanie Giordano,Benjamin O. Fulton,Anbo Zhou,Nicole Negron,Kathryn Lanza,Newton Chan,Angel Coppola,Joyce Chiu,Min Ni,Yi Wei,Gurinder S. Atwal,Annabel Romero Hernandez,Kei Saotome,Yi Zhou,Matthew C. Franklin,Andrea T. Hooper,Shane McCarthy,Sara Hamon,Jennifer D. Hamilton,Hilary M. Staples,Kendra J. Alfson,Ricardo Carrion,Shazia Ali,Thomas Norton,Selin Somersan-Karakaya,Sumathi Sivapalasingam,Gary Herman,David M. Weinreich,Leah Lipsich,Neil Stahl,Andrew J. Murphy,George D. Yancopoulos,Christos A. Kyratsous +36 more
TL;DR: In this paper, the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-CoV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations.
Journal ArticleDOI
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Meagan P. O'Brien,Eduardo Forleo-Neto,Neena Sarkar,Flonza Isa,Peijie Hou,Kuo-Chen Chan,Bret J. Musser,Katharine J. Bar,Ruanne V. Barnabas,Dan H. Barouch,Myron S. Cohen,Christopher B. Hurt,Dale R. Burwen,Mary A. Marovich,Elizabeth R. Brown,Ingeborg Heirman,John D. Davis,Kenneth C. Turner,Divya Ramesh,Adnan Mahmood,Andrea T. Hooper,Jennifer D. Hamilton,Yun-Nam Kim,Lisa A. Purcell,Alina Baum,Christos A. Kyratsous,James P. Krainson,R. Pérez Pérez,Rizwana Mohseni,Bari Kowal,A. Thomas DiCioccio,Gregory P. Geba,Neil Stahl,Leah Lipsich,Ned S. Braunstein,G D Herman,George D. Yancopoulos,David M. Weinreich +37 more
TL;DR: Among asymptomatic SARS-CoV-2 RT-qPCR-positive individuals living with an infected household contact, treatment with subcutaneous casirivimab and imdevimab antibody combination vs placebo significantly reduced the incidence of symptomatic COVID-19 over 28 days.